ABVC Biopharma ROE

Mitä ABVC Biopharma tekee? ABVC Biopharma Inc, trading under the ticker ABVC, is a clinical-stage biopharmaceutical company headquartered in Fremont, California. The company went public via an IPO on November 9, 2004, and currently employs approximately 30 full-time staff. ABVC Biopharma focuses on developing new drugs and medical devices, leveraging licensed technology to improve existing pharmaceutical products for treating various cancer indications and other diseases. The company's research and development efforts involve five compounds licensed from BioLite Inc., designated as ABV-1501, ABV-1502, ABV-1503, ABV-1504, and ABV-1505. As of September 30, 2016, the company had not generated any revenue from its operations. ABVC Biopharma operates in the biotechnology sector, though specific industry classifications are not provided. The company's primary activities include identifying patient populations likely to respond to pharmaceutical products and commercializing these products for licensing in various markets. Despite its focus on clinical-stage development, the company has not yet achieved commercial revenue, reflecting its early-stage status in the biopharmaceutical industry. The firm's headquarters in Fremont, California, serves as its operational base, and it maintains a small workforce of around 30 employees. The company's business model centers on utilizing licensed technology to enhance drug development processes, with an emphasis on cancer treatments and other disease areas. ABVC Biopharma's public listing since 2004 indicates a long-standing presence in the financial markets, though it remains in the development phase without revenue generation. The company's structure and operations are defined by its reliance on licensed compounds and its focus on clinical-stage research without current commercial success. ABVC Biopharma on yksi Eurpooliin suosituimmista yhtiöistä.